LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (NASDAQ: LFMD) announced the lowest nationwide cash-pay pricing for Wegovy and Ozempic at $199 per month for new patients, just hours before its rescheduled Q3 2025 earnings release. Here’s what it means for patients, investors, and the GLP‑1 weight-loss market

LifeMD cuts cash‑pay price for Wegovy and Ozempic to $199/month for 0.25 mg and 0.5 mg starter doses, for the first two fills for new patients in its Weight Management Program. ^[1]
The offer is enabled by LifeMD’s collaboration with Novo Nordisk, expanding access to GLP‑1 therapies via a virtual care model. ^[2]
Q3 2025 earnings release and conference call are scheduled for later today, Nov. 17, after a delay tied to ~$4.6M in revenue‑recognition adjustments (about 1.4% of cumulative revenue for affected periods). ^[3]
Analysts expect Q3 revenue around $62M and EPS near ‑$0.05, with full‑year 2025 revenue estimates around $253M and a broadly “Outperform” rating profile. ^[4]
LifeMD recently sold its majority stake in WorkSimpli at a ~$65M valuation, receiving about $22M in cash and positioning itself as a pure‑play virtual care and pharmacy platform. ^[5]
As of this afternoon, LFMD shares trade around $4.60, modestly lower on the day despite the high‑profile pricing announcement.

LifeMD Announces $199 Cash-Pay Pricing for Wegovy and Ozempic

This morning, LifeMD, Inc. (NASDAQ: LFMD) unveiled what it calls the lowest cash‑pay pricing available nationwide for the GLP‑1 weight‑loss drugs Wegovy and Ozempic, in continued collaboration with Novo Nordisk. ^[6]

Under the new offer:

The 0.25 mg and 0.5 mg starter doses of Wegovy and Ozempic are available for $199 per month.
The pricing applies to new patients paying out of pocket and covers their first two fills. ^[7]
Access is provided through the LifeMD Weight Management Program, which bundles:
- Virtual consultations with LifeMD clinicians
- Diagnostic testing
- Secure messaging via a patient portal
- Education on nutrition, lifestyle, and long‑term metabolic health ^[8]

The move builds on LifeMD’s shift away from compounded GLP‑1s toward direct partnerships with brand‑name manufacturers, a change the company frames as central to its growth strategy and regulatory alignment. ^[9]

For patients who don’t have GLP‑1 coverage through insurance—or face high deductibles—this kind of predictable, program‑based pricing can lower the barrier to medically supervised weight‑loss treatment.

A Pricing Play in a GLP‑1 Arms Race

LifeMD’s update comes against the backdrop of an intensifying price war in the GLP‑1 market:

Novo Nordisk has recently cut direct‑to‑consumer pricing for Wegovy and Ozempic to stay competitive with Eli Lilly’s Zepbound, highlighting growing pressure to make these therapies more affordable. ^[10]
Policy makers in Washington, including the White House, have signaled that improving access to weight‑loss and diabetes drugs is a national priority. ^[11]

LifeMD is trying to differentiate by:

Bundling medication + care
The $199 pricing is wrapped inside a telehealth‑driven program that includes ongoing clinical support, diagnostics, and behavior change resources, not just a script. ^[12]
Leaning on a vertically integrated platform
The company operates a 50‑state affiliated medical group, an affiliated compounding pharmacy, and a U.S.‑based patient care center on a proprietary digital platform—designed to scale nationally while staying inside complex state‑by‑state rules. ^[13]
Targeting self‑pay demand
Many insurers still restrict GLP‑1 coverage for obesity. By focusing on transparent cash‑pay pricing, LifeMD is vying for a large, frustrated self‑pay market segment. ^[14]

An AI‑assisted analysis from AInvest describes LifeMD’s pricing as a “benchmark for affordability” in the GLP‑1 space and notes that its infrastructure and compliance posture are key to scaling this offering. ^[15]

Q3 2025 Earnings: Delayed, Then Due Today

Today’s pricing news lands just hours before LifeMD is expected to report Q3 2025 results after the market close, followed by a 4:30 p.m. ET conference call. ^[16]

Originally slated for November 6, the release was rescheduled to November 17 after LifeMD discovered issues in how revenue had been recognized across several prior periods:

The company identified revenue‑recognition corrections totaling about $4.6 million, affecting 2023, 2024, and the first half of 2025.
Management estimates this represents roughly 1.4% of cumulative revenue for the impacted timeframe.
LifeMD has said the adjustments do not affect cash flow or cash position and don’t materially change how prior results compared to guidance. ^[17]

What Wall Street Is Expecting

Ahead of the report, consensus forecasts point to:

Q3 2025 revenue around $62.1 million
EPS roughly ‑$0.05 per share ^[18]

Full‑year 2025 estimates cluster near:

Revenue of about $250–255 million
Adjusted EBITDA of $27–29 million, with telehealth EBITDA between $14–16 million as the company chases rapid profitability expansion. ^[19]

In Q2 2025, LifeMD reported:

Total revenue of about $62.2 million, up ~23% year over year
Telehealth revenue growth of roughly 30%
Adjusted EBITDA of $7.1 million, a 223% jump year over year, implying an ~11.4% margin. ^[20]

The Q3 print will show whether the company is back on track after a bruising Q2, when it missed revenue and EPS expectations and the stock sold off sharply. ^[21]

Strategy Shift: WorkSimpli Sale and Pure-Play Focus

Today’s GLP‑1 move follows another major strategic step earlier this month: LifeMD’s sale of its majority interest in WorkSimpli Software, a productivity SaaS business it had incubated since 2018. ^[22]

Key deal details:

WorkSimpli was valued at about $65 million enterprise value.
LifeMD sold roughly 80% of its interest, receiving about $22 million in cash at closing, with potential earn‑outs up to $28 million tied to future performance. ^[23]
The sale effectively converts a ~$1.25 million total investment (built over several years) into a substantially larger realized gain, while exiting non‑core SaaS operations. ^[24]

Management has described the transaction as a “defining moment” that lets LifeMD concentrate capital and leadership attention on scaling its virtual care and pharmacy businesses—especially in weight management and cardiometabolic care. ^[25]

For investors, the sale increases balance‑sheet flexibility just as the company:

ramps GLP‑1 programs,
prepares to digest the revenue‑recognition clean‑up, and
navigates legal and regulatory scrutiny.

Legal Overhang: Class Actions and Allegations

Alongside its operational moves, LifeMD faces shareholder litigation risk:

The Gross Law Firm has filed a class action on behalf of investors who bought LFMD shares between May 7 and August 5, 2025. ^[26]
The complaint alleges that LifeMD overstated its competitive position and raised 2025 guidance without fully accounting for rising customer‑acquisition costs, particularly within its RexMD segment and GLP‑1 programs (including Wegovy and Zepbound). ^[27]

Separately, law‑firm alerts (including from Hagens Berman) have flagged similar concerns about alleged misstatements and invite shareholders to explore potential claims. ^[28]

These legal actions are still at an early stage; no court has ruled on the merits. However, they add uncertainty on top of the revenue‑recognition adjustments and will likely be a recurring topic in Q&A with management.

This section summarizes allegations from publicly available complaints and law‑firm notices; it does not take a position on their validity.

How the Market Is Reacting

As of the latest trade, LFMD shares are around $4.60, off roughly 0.6% on the day, with intraday trading between about $4.52 and $5.21.

Despite the stock’s volatile path—particularly after the Q2 miss—analyst sentiment remains relatively constructive:

An analysis of eight brokerage targets puts the average 12‑month price target near $12.88, with a high of $18 and a low of $8, implying significant upside from current levels. ^[29]
GuruFocus data shows a consensus “Outperform”‑style rating (around 2.0 on a 1–5 scale). ^[30]
Cantor Fitzgerald recently reaffirmed an Overweight rating and a $15 price target, calling LifeMD a top pick for 2025 and highlighting management’s goal of ~30% growth over the next three years and an EBITDA margin target of ~25% by Q4 2028 (up from 11.4% in Q2 2025). ^[31]

How today’s GLP‑1 pricing news ultimately affects the stock may depend heavily on what LifeMD discloses on its Q3 call—especially around:

early patient uptake for the $199 offer,
margin implications of lower cash‑pay prices, and
updated 2025 and multi‑year guidance after the WorkSimpli sale and revenue adjustments.

What to Watch Next

For both patients and investors, here are the key catalysts to monitor over the coming days and weeks:

Q3 2025 Earnings Release and Call (Today)
- Actual revenue, EPS, and adjusted EBITDA versus the ~$62M / ‑$0.05 expectations. ^[32]
- Any updated segment disclosure on GLP‑1 programs and telehealth profitability.
Updated 2025 Guidance
- Whether management reiterates or revises full‑year revenue and EBITDA targets post‑WorkSimpli divestiture and pricing changes. ^[33]
GLP‑1 Program Metrics
- Enrollment trends in the Weight Management Program.
- Churn, adherence, and patient‑satisfaction indicators, which will ultimately determine whether lower pricing translates into sustainable growth. ^[34]
Regulatory and Legal Developments
- Any new SEC filings related to the revenue adjustments. ^[35]
- Progress in class‑action suits and any additional investigations or settlements. ^[36]
Broader GLP‑1 Market Moves
- Further pricing shifts by Novo Nordisk and Eli Lilly, and potential government or payer initiatives that could expand—or constrain—coverage for obesity drugs. ^[37]